Join

Compare · BNR vs HUM

BNR vs HUM

Side-by-side comparison of Burning Rock Biotech Limited (BNR) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BNR and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
  • HUM is the larger of the two at $25.96B, about 116.5x BNR ($222.8M).
  • Over the past year, BNR is up 636.5% and HUM is down 18.2% - BNR leads by 654.7 points.
  • HUM has hit the wire 13 times in the past 4 weeks while BNR has been quiet.
  • HUM has more recent analyst coverage (25 ratings vs 2 for BNR).
PerformanceBNR+636.49%HUM-18.25%
2025-04-28+0.00%2026-04-24
MetricBNRHUM
Company
Burning Rock Biotech Limited
Humana Inc.
Price
$20.99+1.84%
$215.14+0.15%
Market cap
$222.8M
$25.96B
1M return
-0.94%
+23.51%
1Y return
+636.49%
-18.25%
Industry
Medical Specialities
Medical Specialities
Exchange
NASDAQ
NYSE
IPO
2020
News (4w)
0
13
Recent ratings
2
25
BNR

Burning Rock Biotech Limited

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer. In addition, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone and BeiGene. The company was founded in 2014 and is headquartered in Guangzhou, China.

HUM

Humana Inc.

Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.